Published on: May 20, 2013 by Aparna Dutt Sharma, Chief Executive Officer, IBEF

In another instance of showcasing the research and development strength of Indian pharmaceutical industry, India has come up with its first indigenously developed vaccine – Rotavac – under public private partnership. The indigenous low-cost vaccine aims at preventing rotavirus diarrhoea and is likely to be priced around INR 54 (US$ 1) per dose, which is 1/40th of the imported vaccines available in the market at present. Subject to clearance from the Drug Controller General of India (DCGI), the vaccine is expected to be launched in the market for sale by next year.